Announcements Trials
Browse Landscape

Phase

Phase 2 79Phase NA 44Phase 1 41Phase 1/2 33Phase 3 23Phase 2/3 6Phase EARLY_PHASE1 5Phase 4 3

Status

Unknown 27Completed 11Recruiting 9Terminated 6Not yet recruiting 6Withdrawn 5Suspended 2Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 6

Conditions

Breast Neoplasms 13Neoplasms 10Carcinoma, Non-Small-Cell Lung 10Lung Neoplasms 9Recurrence 6Prostatic Neoplasms 6Neoplasm Metastasis 6Head and Neck Neoplasms 6Carcinoma, Hepatocellular 6Stomach Neoplasms 5Pancreatic Neoplasms 5Colorectal Neoplasms 5Carcinoma, Squamous Cell 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Multiple Myeloma 4Melanoma 4Liver Neoplasms 4Ovarian Neoplasms 3Myelodysplastic Syndromes 3Lymphoma, Non-Hodgkin 3Lymphoma, Large B-Cell, Diffuse 3Hematologic Neoplasms 3Fatigue 3Esophageal Neoplasms 3Endometrial Neoplasms 3Depression 3Urinary Bladder Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Rectal Neoplasms 2

Interventions

Leucovorin 2Fluorouracil 2menatetrenone 1donafenib 1Sorafenib 1Oxaliplatin 1Injections 1Glucosamine 1Folfox protocol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2/3 × Terminated × Carcinoma, Hepatocellular × Clear all
NCT05171166 2025-12-18

Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial.

Peking University

Phase 2/3 Terminated
18 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT02220088 2019-01-11

The Efficacy and Safety of Retreatment With TAI for Patients Who Showed TACE-resistant: a Randomized Controlled Trial

Sun Yat-sen University

Phase 2/3 Terminated
79 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT00151671 2012-02-27

IMPACT

Rennes University Hospital

Phase 2/3 Terminated
35 enrolled
Gastrointestinal

Fibrosis, Carcinoma, Hepatocellular, Liver Cirrhosis, Liver Neoplasms

NCT00165633 2008-12-09

A Phase II/III Clinical Study on Inhibitory Effects of E0167 on Recurrence of Hepatocellular Carcinoma

Eisai Inc.

Phase 2/3 Terminated
540 enrolled
Gastrointestinal

Carcinoma, Hepatitis B, Hepatitis C, Carcinoma, Hepatocellular, Recurrence

NCT00034333 2005-06-24

Safety and Efficacy of Doxorubicin Adsorbed to Magnetic Beads Vs. IV Doxorubicin in Treating Liver Cancer

FeRx

Phase 2/3 Terminated
240 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT00057382 2005-06-24

T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma Patients

Tularik

Phase 2/3 Terminated
750 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡